000307663 001__ 307663
000307663 005__ 20260219120950.0
000307663 0247_ $$2doi$$a10.1093/ckj/sfaf387
000307663 0247_ $$2pmid$$apmid:41536568
000307663 0247_ $$2pmc$$apmc:PMC12798722
000307663 0247_ $$2ISSN$$a2048-8505
000307663 0247_ $$2ISSN$$a1753-0784
000307663 0247_ $$2ISSN$$a1753-0792
000307663 0247_ $$2ISSN$$a2048-8513
000307663 037__ $$aDKFZ-2026-00120
000307663 041__ $$aEnglish
000307663 082__ $$a610
000307663 1001_ $$00000-0002-5821-893X$$aKraft, Leonie$$b0
000307663 245__ $$aChanging microbiology and outcomes of PD-associated peritonitis over four decades.
000307663 260__ $$aOxford$$bOxford Univ. Press$$c2026
000307663 3367_ $$2DRIVER$$aarticle
000307663 3367_ $$2DataCite$$aOutput Types/Journal article
000307663 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768572489_1240525
000307663 3367_ $$2BibTeX$$aARTICLE
000307663 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307663 3367_ $$00$$2EndNote$$aJournal Article
000307663 520__ $$aPeritoneal dialysis (PD)-associated peritonitis remains a major complication affecting patient outcomes and modality survival. This study aims to evaluate temporal trends in pathogen distribution and antibiotic susceptibility over four decades as well as clinical outcomes in PD-associated peritonitis.We retrospectively analyzed 832 peritonitis cultures of PD patients across four decades from 1979 to 2024 treated at Robert Bosch Hospital, Stuttgart (Germany). For longitudinal comparison of pathogen distribution and antibiotic susceptibility, the study period was divided into four time periods: P1 (1979-1992), P2 (1993-2003), P3 (2004-2014), and P4 (2015-2024). Clinical response and outcomes were assessed in P4.Gram-positive bacteria was the most frequent causative organisms (56%), followed by Gram-negative bacteria (30%) and culture-negative peritonitis (CNP, 13%). Gram-negative peritonitis increased significantly in P4 compared to P1-P3, while coagulase-negative staphylococci (CNS) declined from 31% in P1 to 14% in P4 (P = .0446). Vancomycin susceptibility among Gram-positive organisms remained high, whereas cefazolin susceptibility changed over time. In P4, the overall cure rate was 63%, with the highest in gram-positive (72%) and lowest in polymicrobial peritonitis (43%).Regarding clinical outcomes, transition to permanent hemodialysis (HD) was significantly more frequent in Gram-negative than Gram-positive peritonitis (27% vs. 12%; P = .03). Both catheter removal and transition to permanent HD occurred significantly more often in polymicrobial peritonitis (54% and 40%) compared with Gram-positive (24% and 12%; P = .001 and P = .0008) and CNP (30% and 17%; P = .01 and P = .04). Regarding individual pathogens, Staphylococcus aureus (MSSA) was associated with a significantly higher catheter removal rate compared to other Gram-positive organisms.Our findings show temporal changes of microbiological spectrum of PD-associated peritonitis over four decades. Polymicrobial and Gram-negative peritonitis were associated with poorer outcomes, emphasizing the need for ongoing microbiological surveillance and antibiotic stewardship to optimize PD care.
000307663 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000307663 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307663 650_7 $$2Other$$aclinical response
000307663 650_7 $$2Other$$along-term observation
000307663 650_7 $$2Other$$amicrobiological pattern
000307663 650_7 $$2Other$$aperitoneal dialysis
000307663 650_7 $$2Other$$aperitonitis
000307663 7001_ $$0P:(DE-He78)1b606cab47064dc2e401f0aaa9113511$$aOppold, Julia$$b1$$udkfz
000307663 7001_ $$aKitterer, Daniel$$b2
000307663 7001_ $$aBraun, Niko$$b3
000307663 7001_ $$aKimmel, Martin$$b4
000307663 7001_ $$aTwardowski, Laura$$b5
000307663 7001_ $$aBiegger, Dagmar$$b6
000307663 7001_ $$aOberacker, Tina$$b7
000307663 7001_ $$aSchwab, Andrea$$b8
000307663 7001_ $$aMerz, Silke$$b9
000307663 7001_ $$aWirkus, Katharina$$b10
000307663 7001_ $$aSchulte, Kevin$$b11
000307663 7001_ $$aSchmitt, Roland$$b12
000307663 7001_ $$aKielstein, Jan T$$b13
000307663 7001_ $$aEden, Gabriele$$b14
000307663 7001_ $$aSchmid, Nico$$b15
000307663 7001_ $$00000-0002-6770-3056$$aSchricker, Severin$$b16
000307663 7001_ $$aLatus, Joerg$$b17
000307663 7001_ $$00000-0001-7300-8132$$aSchanz, Moritz$$b18
000307663 773__ $$0PERI:(DE-600)2656786-6$$a10.1093/ckj/sfaf387$$gVol. 19, no. 1, p. sfaf387$$n1$$psfaf387$$tClinical kidney journal$$v19$$x2048-8505$$y2026
000307663 8564_ $$uhttps://inrepo02.dkfz.de/record/307663/files/sfaf387.pdf$$yOpenAccess
000307663 8564_ $$uhttps://inrepo02.dkfz.de/record/307663/files/sfaf387.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000307663 909CO $$ooai:inrepo02.dkfz.de:307663$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000307663 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1b606cab47064dc2e401f0aaa9113511$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000307663 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000307663 9141_ $$y2026
000307663 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN KIDNEY J : 2022$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-03T10:36:46Z
000307663 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-03T10:36:46Z
000307663 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000307663 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-13
000307663 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000307663 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000307663 980__ $$ajournal
000307663 980__ $$aVDB
000307663 980__ $$aUNRESTRICTED
000307663 980__ $$aI:(DE-He78)E010-20160331
000307663 9801_ $$aFullTexts